hydroxychloroquine has been researched along with sulfasalazine in 214 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (4.21) | 18.7374 |
| 1990's | 37 (17.29) | 18.2507 |
| 2000's | 53 (24.77) | 29.6817 |
| 2010's | 95 (44.39) | 24.3611 |
| 2020's | 20 (9.35) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| van de Putte, LB; van Leeuwen, MA; van Riel, PL; van Rijswijk, MH; van't Hof, MA; Wijnands, MJ | 1 |
| McConkey, B | 1 |
| Capell, HA; Russell, RI; Sturrock, RD; Taha, AS | 1 |
| Nuver-Zwart, IH; van de Putte, LB; van der Heijde, DM; van Riel, PL | 2 |
| van de Putte, LB; van der Heijde, DM; van Riel, PL | 2 |
| Allebes, WA; Boerbooms, AM; van de Putte, LB; van Riel, PL; Wijnands, MJ | 1 |
| Gribnau, FW; Nuver-Zwart, IH; vad de Putte, LB; van der Heijde, DM; van Riel, PL | 1 |
| Gribnau, FW; Nuver-Zwart, IH; van de Putte, LB; van Riel, PL | 1 |
| Muirden, KD | 1 |
| Clegg, DO; Ward, JR | 1 |
| Pinals, RS | 1 |
| Bird, HA; Dixon, JS; Greenwood, M | 1 |
| Ehrenpreis, T; Gierup, J; Lagercrantz, R | 1 |
| Carotti, M; Cervini, C; Salaffi, F | 1 |
| Emery, HM | 1 |
| Egsmose, C; Faarvang, KL; Hansen, TM; Ingeman-Nielsen, M; Kryger, P; Pødenphant, J | 1 |
| Davis, MJ; Dawes, PT | 1 |
| Tett, SE | 1 |
| van 't Hof, M; van de Putte, LB; van der Heijde, DM; van Riel, PL | 1 |
| Astbury, C; Bird, HA; Dixon, JS; Hill, J; Le Gallez, P; Platt, R | 1 |
| Munro, RA; Sturrock, RD | 1 |
| Prevoo, ML; van 't Hof, MA; van de Putte, LB; van Gestel, AM; van Riel, PL; van Rijswijk, MH | 1 |
| van de Putte, LB; van Riel, PL | 1 |
| Drymalski, W; Eckhoff, PJ; Erikson, N; Garwood, V; Haire, CE; Klassen, LW; Klein, H; Maloley, P; Moore, GF; O'Dell, JR; Palmer, W; Wees, S | 1 |
| Arkfeld, DG; Stohl, W | 1 |
| DeMarco, DM; Liu, NY; Zurier, RB | 1 |
| van de Putte, LB; van Gestel, AM; van Riel, PL | 1 |
| Drymalski, W; Erikson, N; Haire, C; Klassen, LW; Maloley, P; Moore, GF; O'Dell, JR; Palmer, W; Wees, S | 1 |
| Haagsma, CJ; van Riel, PL | 1 |
| Caspi, D; Elkayam, O; Segal, R; Yaron, M; Zhukovsky, G | 1 |
| Wollenhaupt, J; Zeidler, H | 1 |
| Hannonen, PJ; Kautiainen, HJ; Sokka, TM | 1 |
| Drymalski, W; Eckhoff, PJ; Gaur, L; Gersuk, VH; Haire, C; Klassen, LW; Moore, GF; Nepom, BS; Nepom, GT; O'Dell, JR; Palmer, W; Thiele, G; Wees, S | 1 |
| O'Dell, JR | 1 |
| Altindağ, ZZ; Hasçelik, Z; Inanici, F; Sahin, G | 1 |
| Ahonen, J; Blåfield, H; Forsberg, S; Friman, C; Hakala, M; Hakola, M; Hannonen, P; Ilva, K; Järvinen, P; Julkunen, H; Kautiainen, H; Koota, K; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luukkainen, R; Möttönen, T; Nissilä, M; Paimela, L; Pälvimäki, I; Piirainen, H; Puolakka, K; Vuori, K; Yli-Kerttula, U | 1 |
| Klassen, LW; Moore, GF; O'Dell, JR | 1 |
| Schattner, A | 1 |
| Diani, A; Docsa, S; Giobbie-Hurder, A; Henderson, W; Reda, D; Weinblatt, ME; Williams, D | 1 |
| de Bandt, M | 1 |
| O'Dell, JR; Scott, DL | 1 |
| Mikuls, TR; O'Dell, J | 1 |
| Bijlsma, JW; Blaauw, AA; Brus, HL; Haanen, HC; Heurkens, AH; Hofman, DM; Jacobs, JW; Kruize, AA; Schenk, Y; ter Borg, EJ; van Albada-Kuipers, GA; van Booma-Frankfort, C; van der Veen, MJ; van Jaarsveld, CH | 1 |
| Hollister, JR | 1 |
| Bombardier, C; Maetzel, A; Strand, V; Tugwell, P; Wells, G; Wong, A | 1 |
| Kremer, JM | 1 |
| Capell, HA | 1 |
| O'Dell, J | 1 |
| Wasko, MC; Wildy, KS | 1 |
| Pisetsky, DS; St Clair, EW | 1 |
| Franzen, P; Gripenberg-Gahmberg, M; Hannonen, P; Helve, T; Ilonen, J; Kaipiainen-Seppänen, O; Kautiainen, H; Korpela, M; Koski, J; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Myllykangas-Luosujärvi, R; Nissilä, M | 1 |
| Scott, DL | 1 |
| Beaurain, D; Delcambre, B; Duquesnoy, B; Flipo, RM; Grardel, B; Marguerie, L | 1 |
| Blakely, K; Churchill, M; Eckhoff, PJ; Felt, J; Fernandez, A; Hadley, S; Haire, C; Klassen, L; Leff, R; Mallek, J; Moore, G; O'Dell, JR; Palmer, W; Paulsen, G; Stoner, J; Waytz, P; Wees, S | 1 |
| Jiang, L; Ni, L; Zhao, N | 1 |
| Kellner, H; Schiemann, U | 1 |
| Baranauskaite, A; Misiūniene, N | 1 |
| Gross, WL; Schnabel, A | 1 |
| Kaarela, K; Klaukka, T | 1 |
| Ayoub, N; Barete, S; Francès, C; Piette, JC | 1 |
| Førre, Ø; Haga, HJ; Johnsen, V; Kvien, TK; Mikkelsen, K; Nordvåg, BY; Rødevand, E | 1 |
| Conaghan, PG; Emery, P; Green, MJ; Karim, Z; Marzo-Ortega, H; Proudman, S; Quinn, MA; Wakefield, RJ | 1 |
| Bar-Din, M; Griffiths, RI; Herbert, RJ; MacLean, CH; Sullivan, EM; Yelin, EH | 1 |
| Blåfield, H; Hakala, M; Hannonen, P; Julkunen, H; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Luukkainen, R; Möttönen, T; Paimela, L; Puolakka, K; Vuori, K | 1 |
| Weinblatt, ME | 1 |
| Apras, S; Calgüneri, M; Cobankara, V; Ertenli, I; Haznedaroglu, IC; Kiraz, S; Ozatli, D; Oztürk, MA; Türk, T | 1 |
| Emery, P; Suarez-Almazor, M | 1 |
| Issa, SN; Ruderman, EM | 1 |
| Ahonen, J; Forsberg, S; Hakala, M; Hannonen, P; Järvinen, P; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Möttönen, T; Puolakka, K | 1 |
| Apraş, S; Calgüneri, M; Cobankara, V; Ertenli, I; Kiraz, S; Oztürk, MA | 1 |
| Fath, R | 1 |
| Aries, PM; Reinhold-Keller, E | 1 |
| Blakely, K; Fernandez, A; Haire, C; Leff, R; O'Dell, JR; Palmer, W; Petersen, K; Schned, E | 1 |
| Lioté, F | 1 |
| Caughey, GE; Cleland, LG; James, MJ; Proudman, SM | 1 |
| Resman-Targoff, BH | 1 |
| Dijkmans, BA; Nurmohamed, MT; Twisk, JW; van Halm, VP; Voskuyl, AE | 1 |
| Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D | 1 |
| Ayres, OC; Caughey, GE; Cleland, LG; Goldblatt, F; Hill, CL; James, MJ; Keen, HI; Lee, AT; Proudman, SM; Rischmueller, M; Stamp, LK | 1 |
| Giles, JT; Golding, A; Haque, UJ | 1 |
| Matsuda, T; Ohtsubo, H | 1 |
| Bingham, CO; Miner, MM | 1 |
| Cleland, LG; Gillis, D; Hissaria, P; James, HM; Lester, S; Proudman, SM; Somogyi, AA | 1 |
| Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M | 1 |
| Capell, HA; Kincaid, W; McMahon, AD; Porter, DR; Saunders, SA; Stirling, A; Vallance, R | 1 |
| Bochkova, AG; Bunchuk, NV; Gubar', EE | 1 |
| Boers, M; Dijkmans, BA; Garnero, P; Kerstens, PJ; Lems, WF; van Tuyl, LH; Voskuyl, AE | 1 |
| Anuradha, V; Chopra, A; Kunjir, V; Lagoo-Joshi, V; Saluja, M; Salvi, S | 1 |
| Brasington, R | 1 |
| Allaart, CF; Dijkmans, BA; Huizinga, TW; Kerstens, PJ; Klarenbeek, NB | 1 |
| Hakala, M; Hannonen, P; Järvenpää, S; Julkunen, H; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Luosujärvi, R; Möttönen, T; Puolakka, K; Rantalaiho, V | 1 |
| Akre, F; Bratt, J; Chatzidionysiou, A; Cöster, L; Dackhammar, C; Ernestam, S; Forslind, K; Geborek, P; Hellström, H; Ljung, L; Oding, R; Petersson, IF; Teleman, A; Theander, J; Thörner, A; van Vollenhoven, RF; Waltbrand, E; Wörnert, M; Zickert, A | 1 |
| Díaz, J; González, A; Mora, C; Quintana, G | 1 |
| Blåfield, H; Hannonen, P; Järvenpää, S; Karjalainen, A; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Puolakka, K; Rantalaiho, V | 1 |
| Mäkinen, H; Möttönen, T; Puolakka, K | 1 |
| Arkfeld, D; Fong, TL; Yang, D | 1 |
| Brismar, K; Engvall, IL; Hafström, I; Tengstrand, B | 1 |
| Partlett, R; Roussou, E | 1 |
| Bambery, P; Jose, V; Mittal, N; Mittal, R; Sharma, A; Wanchu, A | 1 |
| Aalto, K; Honkanen, V; Kröger, L; Lahdenne, P; Malin, M; Putto-Laurila, A; Tarkiainen, M; Tynjälä, P; Vähäsalo, P | 1 |
| Ganu, AS; Ganu, MA | 1 |
| Arbogast, PG; Chen, L; Curtis, JR; Delzell, E; Griffin, MR; Grijalva, CG; Herrinton, L; Kawai, VK; Liu, L; Mitchel, EF; Ouellet-Hellstrom, R; Solomon, DH; Stein, CM | 1 |
| Albertsson, K; Bratt, J; Chatzidionysiou, K; Ernestam, S; Forslind, K; Geborek, P; Petersson, IF; van Vollenhoven, RF | 1 |
| Bathon, JM; Bridges, SL; Cofield, SS; Curtis, JR; Howard, G; McVie, T; Moreland, LW; O'Dell, JR; Paulus, HE; St Clair, EW; van der Heijde, D; Zhang, J | 1 |
| Barendregt, PJ; de Jager, MH; de Jong, PH; de Sonnaville, PB; Gerards, AH; Grillet, BA; Hazes, JM; Huisman, M; Luime, JJ; van der Lubbe, PA; van Zeben, D; Weel, AE | 1 |
| Miller, AV; Ranatunga, SK | 1 |
| Bridges, SL; Cofield, SS; Curtis, JR; Maska, LB; Mikuls, TR; Moreland, LW; O'Dell, JR; Sayles, HR | 1 |
| Blåfield, H; Hannonen, PJ; Ilva, K; Julkunen, HA; Kaipiainen-Seppänen, O; Karjalainen, A; Kauppi, MJ; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luosujärvi, R; Luukkainen, R; Moilanen, E; Möttönen, T; Paimela, L; Puolakka, K; Uutela, T | 1 |
| Bratt, J; Ernestam, S; Geborek, P; Karlsson, JA; Neovius, M; Nilsson, JÅ; Petersson, IF; van Vollenhoven, RF | 1 |
| Hannonen, PJ; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Möttönen, T; Rantalaiho, VM | 1 |
| Bathon, JM; Bridges, SL; Charles-Schoeman, C; Chen, L; Cofield, SS; Curtis, JR; Dell'Italia, LJ; Moreland, LW; Navarro-Millán, I; O'Dell, JR; Paulus, HE; Yang, S | 1 |
| Forslind, K; Geborek, P; Petersson, IF; Rezaei, H; Saevarsdottir, S; van Vollenhoven, RF | 1 |
| Bridges, SL; Cofield, SS; Curtis, JR; McVie, T; Mikuls, TR; Moreland, LW; Navarro-Millán, I; O'Dell, J; Ranganath, VK; Reynolds, RJ | 1 |
| Kiely, PD; McWilliams, DF; Walsh, DA; Young, A | 1 |
| Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK | 1 |
| Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Speyer, I; van Oosterhout, M; Visser, K; Wevers-de Boer, KV | 1 |
| Ahluwalia, V; Anis, AH; Brophy, M; Cannella, AC; Keystone, E; Kunkel, G; Leatherman, S; Lew, RA; Mikuls, TR; O'Dell, JR; Phibbs, CS; Taylor, TH; Warren, SR | 1 |
| Bathon, JM; McMahon, DJ | 1 |
| Yelin, E | 1 |
| Bratt, J; Eriksson, JK; Ernestam, S; Geborek, P; Neovius, M; Petersson, IF; van Vollenhoven, RF | 1 |
| Chatzidionysiou, K; van Vollenhoven, RF | 1 |
| Hakala, M; Jämsen, E; Kauppi, MJ; Lehto, MU; Malmivaara, A; Virta, LJ | 1 |
| Cleland, LG; Flabouris, K; James, MJ; Lee, AT; Metcalf, RG; Proudman, SM; Rischmueller, M; Spargo, LD; Sullivan, TR; Wechalekar, MD | 1 |
| Krüger, K | 1 |
| Chen, DY; Chen, HH; Chen, YM; Chou, P; Chou, YJ; Huang, N; Lai, KL; Lin, CH | 1 |
| Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Harbers, JB; Heimans, L; Huizinga, TW; Kälvesten, J; Steup-Beekman, M; van Oosterhout, M; Visser, K; Wevers-de Boer, KV | 1 |
| Allaart, CF; Goekoop-Ruiterman, YP; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Koudijs, KK; Lard, LR; Steup-Beekman, GM; Visser, K; Wevers-de Boer, KV | 1 |
| Albertsson, K; Ernestam, S; Forslind, K; Geborek, P; Petersson, I; Rezaei, H; Saevarsdottir, S; van Vollenhoven, RF | 1 |
| Bratt, J; Eriksson, JK; Ernestam, S; Geborek, P; Karlsson, JA; Neovius, M; Petersson, IF; van Vollenhoven, RF | 1 |
| de Jong, PH; de Sonnaville, PB; Gerards, AH; Han, HK; Hazes, JM; Huisman, M; Luime, JJ; van der Lubbe, PA; van Krugten, MV; van Schaeybroeck, B; van Zeben, D; Weel, AE | 1 |
| Bolce, R; Chernoff, D; Cruickshank, SE; Forslind, K; Geborek, P; Hambardzumyan, K; Petersson, IF; Saevarsdottir, S; Sasso, EH; van Vollenhoven, RF | 1 |
| Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P | 1 |
| Batat, E; Bitterman, H; Cohen, AD; Cohen, S; Comanesther, D; Feldhamer, I; Greenberg-Dotan, S; Shalom, G; Zisman, D | 1 |
| Hämäläinen, M; Moilanen, E; Moilanen, T; Tuure, L | 1 |
| Anelli, MG; Cacciapaglia, F; Covelli, M; Iannone, F; Lapadula, G; Rinaldi, A; Scioscia, C; Serafino, L | 1 |
| Foster, DJ; Proudman, SM; Upton, RN; Wiese, MD; Wojciechowski, J | 1 |
| Hakala, M; Häkkinen, A; Järvenpää, S; Kautiainen, H; Salomaa, S; Uutela, T | 1 |
| Ernestam, S; Forslind, K; Geborek, P; Karlsson, JA; Kastbom, A; Klareskog, L; Lundberg, K; Petersson, IF; Saevarsdottir, S; van Vollenhoven, RF | 1 |
| Fautrel, B; Gaujoux-Viala, C; Tsonaka, R; van der Helm-van Mil, AH; van Nies, JA | 1 |
| Chen, CJ; Cheng, TT; Lin, JC; Lin, KM | 1 |
| Forslind, K; Levitsky, A; van Vollenhoven, RF | 1 |
| Bonafede, M; Collier, DH; Harrison, DJ; Johnson, BH; Shah, N; Tang, DH | 1 |
| Barton, A; Chinoy, H; Fu, B; Griffiths, CE; Hyrich, K; Isaacs, JD; Jani, M; Morgan, AW; Plant, D; Warren, RB; Wilson, AG | 1 |
| Blåfield, H; Eklund, KK; Ilva, K; Kaipiainen-Seppänen, O; Karjalainen, A; Kautiainen, H; Korpela, M; Kuusalo, L; Leirisalo-Repo, M; Puolakka, K; Rantalaiho, V; Valleala, H | 1 |
| Cummins, L; Duggan, E; Katikireddi, VS; Pahau, H; Shankaranarayana, S; Su, KY; Thomas, R; Videm, V | 1 |
| Bokarewa, MI; Erlandsson, MC; Levitsky, A; van Vollenhoven, RF | 1 |
| Horneff, G; Hügle, B | 1 |
| Akdemir, G; Allaart, CF; Boer, KV; de Sonnaville, PB; Goekoop-Ruiterman, YP; Grillet, BA; Heimans, L; Huizinga, TW; Lard, LR; Molenaar, ET; Peeters, AJ; Steup-Beekman, GM; van Groenendael, JH | 1 |
| Danaei, G; Desai, RJ; Kim, SC; Liao, KP; Schneeweiss, S; Solomon, DH | 1 |
| Brill, G; Choudhry, NK; Krumme, AA; Matlin, OS; Pezalla, EJ; Shrank, WH; Solomon, DH; Sparks, JA | 1 |
| Eriksson, JK; Ernestam, S; Miller, H; Neovius, M; Petersson, IF; van Vollenhoven, RF; Vivar, N; Wallman, JK | 1 |
| Bridges, SL; Cofield, S; Curtis, JR; Jalal, H; Michaud, K; Mikuls, TR; Moreland, LW; O'Dell, JR | 1 |
| Gogia, SB; Malaviya, AN | 1 |
| Cannon, GW; Curtis, JR; Harrison, DJ; Leng, J; Mikuls, TR; Sauer, BC; Tang, D; Teng, CC | 1 |
| Gerosa, M; Meroni, PL; Schioppo, T | 1 |
| Bansback, N; Lacaille, D; Shojania, K | 1 |
| Cleland, LG; Hall, C; Lee, AT; McWilliams, L; Metcalf, RG; Proudman, SM; Sorich, MJ; Spargo, LD; Wabe, NT; Wechalekar, MD; Wiese, MD | 1 |
| Bathon, J; Charles-Schoeman, C; Chen, L; Cofield, SS; Curtis, JR; Elashoff, D; Louis Bridges, S; Moreland, LW; Navarro-Millán, I; O'Dell, J; Paulus, H; Reddy, ST; Shahbazian, A; Wang, X; Yang, S; Yin Lee, Y | 1 |
| Baillet, A; Bernard, AC; Clay, M; Gaudin, P; Mazouyès, A | 1 |
| Bolce, RJ; Ernestam, S; Forslind, K; Hambardzumyan, K; Petersson, IF; Saevarsdottir, S; van Vollenhoven, RF; Wallman, JK | 1 |
| Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S | 1 |
| Chen, DY; Chen, YM; Liao, TL; Liu, HJ | 1 |
| Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A | 1 |
| Aaltonen, K; Asikainen, J; Ekman, P; Hannonen, P; Isomäki, P; Kauppi, M; Kautiainen, H; Kortelainen, S; Kuusalo, L; Laiho, K; Mäkinen, H; Mali, M; Nyrhinen, S; Paltta, J; Pirilä, L; Puurtinen-Vilkki, M; Rannio, T; Sokka, T; Taimen, K; Uotila, T; Yli-Kerttula, T | 1 |
| Brophy, M; Lew, R; Mikuls, T; O'Dell, J; Peper, SM; Rybin, D; Wu, H | 1 |
| Combe, B; De Bandt, M; Lukas, C; Mary, J; Morel, J | 1 |
| Ciechomska, M; Horsburgh, S; O'Reilly, S | 1 |
| Dangi, A; Rajput, R; Singh, H | 1 |
| Guo, Y; Nagpal, S; Proudman, SM; Smith, MD; Walsh, AM; Wechalekar, MD; Weedon, H; Yin, X | 1 |
| Cleland, LG; Lee, A; McWilliams, L; Proudman, S; Wabe, N; Wechalekar, MD; Wiese, MD; Wojciechowski, J | 1 |
| Akdemir, G; Allaart, CF; Bergstra, SA; de Sonnaville, PBJ; Goekoop, RJ; Grillet, BAM; Heimans, L; Huizinga, TWJ; Lard, LR; Peeters, AJ; Steup-Beekman, GM; van Groenendael, JHLM; van Oosterhout, M | 1 |
| Bombardier, C; Hazlewood, GS; Marshall, D; Tomlinson, G | 1 |
| Chen, CH; Chen, CM; Chiou, JY; Leong, PY; Li, YC; Lin, LC; Tam, HW; Wang, YH; Wei, JC | 1 |
| Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC | 1 |
| Allaart, CF; Bergstra, SA; Chopra, A; Govind, N; Landewé, RBM; Murphy, EA; Ramiro, S; Silva, C | 1 |
| Cannon, GW; Curtis, JR; Erhardt, DP; Mikuls, TR; Sauer, BC; Teng, CC | 1 |
| Bazzichi, L; Bianchino, L; Caporali, R; Nacci, F; Sinigaglia, L | 1 |
| Cappelli, LC; Darrah, E; Mikuls, TR; O'Dell, JR; Rosen, A; Yu, F | 1 |
| Bertolo, MB; Brenol, CV; Castelar Pinheiro, GDR; Cruz, BA; de Albuquerque, CP; de Freitas, MVC; Duarte, ALBP; Giorgi, RDN; Gomides, APM; Kakehasi, AM; Laurindo, IMM; Louzada-Júnior, P; Mota, LMHD; Pereira, IA; Ubirajara Silva de Souza, MPG; Xavier, RM | 1 |
| Li, RN; Lin, CH; Lin, YZ; Ou, TT; Sung, WY; Tsai, WC; Tseng, CC; Wu, CC; Yen, JH | 1 |
| Atia, NN; El-Koussi, WM; Hammam, N; Saleh, GA | 1 |
| Boulos, D; Hall, C; McWilliams, L; Metcalf, RG; Proudman, SM; Wicks, IP | 1 |
| Amiri, N; Baldwin, C; De Vera, MA; Rebić, N; Sayre, EC; Zusman, EZ | 1 |
| Bessette, L; Haraoui, B; Lazovskis, J; Pope, J; Rampakakis, E; Sampalis, JS; Vaillancourt, J | 1 |
| Li, J; Xie, W; Zhang, Z | 1 |
| Cantagrel, A; Combe, B; Daïen, C; Debandt, M; Fautrel, B; Lukas, C; Mary, J; Morel, J | 1 |
| Chu, AD; Deodhar, A; Everding, A; Kim, TH; Kishimoto, M; Maksymowych, WP; Pangan, AL; Sieper, J; Song, IH; Sui, Y; van den Bosch, F; van der Heijde, D; Wang, X | 1 |
| Aalto, K; Kröger, L; Lahdenne, P; Tarkiainen, M; Tynjälä, P; Vähäsalo, P | 1 |
| Bértolo, MB; Bonfiglioli, KR; Brenol, CV; da Mota, LMH; da Rocha Castelar Pinheiro, G; de Albuquerque, CP; de Fátima Lobato da Cunha Sauma, M; Giorgi, RDN; Gomides, APM; Júnior, PL; Pereira, IA; Radominski, SC; Resende Guimarães, MFB; Santos, ABV | 1 |
| Curtis, JR; Greenberg, J; Harrold, LR; Kremer, JM; Palmer, JL; Pappas, DA; Reed, GW | 1 |
| Ernestam, S; Jöud, A; Lampa, J; Olofsson, T; Saevarsdottir, S; Schelin, MEC; van Vollenhoven, R; Wallman, JK | 1 |
| Padern, G; Pers, YM | 1 |
| Hammad, I; Porter, TF | 1 |
| Askling, J; Ernestam, S; Miller, H; Neovius, M; Petersson, IF; Saevarsdottir, S; Söderling, J; van Vollenhoven, R; Wallman, JK | 1 |
| Baecklund, E; Bakland, G; Brodin, E; Cagnotto, G; Ellingsen, T; Faustini, F; Grondal, G; Grøn, KL; Gudbjornsson, B; Haavardsholm, EA; Heiberg, MS; Hendricks, O; Hetland, ML; Hultgård Ekwall, AK; Husmark, T; Hyldstrup, LH; Hørslev-Petersen, K; Just, SA; Kapetanovic, M; Krabbe, S; Lampa, J; Larsson, P; Laurberg, TB; Lend, K; Lindqvist, J; Ljoså, MA; Lorenzen, T; Nordström, D; Nurmohamed, M; Olsen, IC; Olsson, ÅR; Rizk, M; Rudin, A; Söderbergh, A; Sokka-Isler, T; Stevens, DJ; Tuompo, R; Twisk, J; Uhlig, T; Uhrenholt, L; van Vollenhoven, R; Vedder, D; Østergaard, M | 1 |
| Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W | 1 |
| C Kapetanovic, M; Einarsson, JT; Geborek, P; Källmark, H; Nilsson, JÅ; Olofsson, T; Saxne, T | 1 |
| Chen, J; Cooper, D; Norling, LV | 1 |
| Aga, AB; Bakland, G; Fremstad, H; Haavardsholm, EA; Hansen, IJW; Hansen, IM; Haukeland, H; Høili, CA; Kvien, TK; Lexberg, Å; Lillegraven, S; Ljoså, MA; Madland, TM; Moholt, E; Olsen, IC; Paulshus Sundlisæter, N; Sexton, J; Solomon, DH; Spada, C; Uhlig, T; van der Heijde, D | 1 |
| Belani, PJ; Kavadichanda, CG; Negi, VS | 1 |
| Bruun, JM; Hundahl, MP; Kjolby, M; Kragstrup, TW; Mikkelsen, RR; Rodríguez-Carrio, J; Torp, CK | 1 |
| Askling, J; Barbulescu, A; Frisell, T; Kim, SC; Saevarsdottir, S | 1 |
| Ahmed, S; Carsons, SE; De Leon, J; Kasselman, LJ; Konig, J; Reiss, AB; Renna, HA | 1 |
| Barrett, R; Culliford, D; Edwards, CJ; Fraser, S; Lin, SX | 1 |
| Barnabe, C; Bullen, J; Bunzli, S; Conley, B; Grainger, R; Gunatillake, T; Lin, I; Nikpour, M; O'Brien, P; Persaud, J | 1 |
42 review(s) available for hydroxychloroquine and sulfasalazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Organogold Compounds; Penicillamine; Sulfasalazine | 1991 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical Trials as Topic; Gastrointestinal Diseases; Glomerulonephritis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myasthenia Gravis; Myositis; Pemphigus; Penicillamine; Pyrithioxin; Sulfasalazine; Thrombocytopenia | 1986 |
Treatment of juvenile rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Erythropoietin; gamma-Globulins; Glucocorticoids; Humans; Hydroxychloroquine; Methotrexate; Nutritional Physiological Phenomena; Pain Management; Pregnenediones; Sulfasalazine | 1993 |
Clinical pharmacokinetics of slow-acting antirheumatic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Chloroquine; Delayed-Action Preparations; Humans; Hydroxychloroquine; Organogold Compounds; Penicillamine; Sulfasalazine | 1993 |
Slow-acting antirheumatic drugs. Drug interactions of clinical significance.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Gold; Humans; Hydroxychloroquine; Penicillamine; Sulfasalazine | 1995 |
Rheumatoid arthritis--changing theories and treatment modalities.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Patient Satisfaction; Sulfasalazine | 1995 |
Combination of second-line antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine; Treatment Outcome | 1997 |
[Combined administration of long-acting antirheumatic drugs in the treatment of chronic polyarthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclosporins; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Hydroxychloroquine; Immunosuppressive Agents; Methotrexate; Organogold Compounds; Penicillamine; Prospective Studies; Randomized Controlled Trials as Topic; Sulfasalazine | 1997 |
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine; Treatment Outcome | 1998 |
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Male; Middle Aged; Multicenter Studies as Topic; Penicillamine; Randomized Controlled Trials as Topic; Sulfasalazine | 1999 |
[Rheumatoid polyarthritis: etiology, diagnosis, course, treatment principles].
Topics: Adrenal Cortex Hormones; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cytokines; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Organogold Compounds; Prognosis; Radiography; Sulfasalazine | 1999 |
Rheumatoid arthritis: new developments in the use of existing therapies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Prednisolone; Sulfasalazine | 1999 |
Medical treatment of adolescents with rheumatic disease.
Topics: Adolescent; Adolescent Medicine; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Pregnancy; Rheumatic Diseases; Sulfasalazine | 1998 |
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Methotrexate; Organogold Compounds; Sulfasalazine; Treatment Refusal | 2000 |
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Costs; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Risk Factors; Sulfasalazine | 2001 |
Disease modifying antirheumatic drugs: longterm safety issues.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Methotrexate; Safety; Sulfasalazine; Treatment Outcome | 2001 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones | 2001 |
Progress in the treatment of rheumatoid arthritis.
Topics: Analgesics; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclosporine; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Minocycline; Penicillamine; Receptors, Tumor Necrosis Factor; Sulfasalazine | 2001 |
Advances in the medical management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Receptors, Tumor Necrosis Factor; Steroids; Sulfasalazine; Treatment Outcome | 2002 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Etanercept; Gastrointestinal Diseases; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Rheumatic Diseases; Stomach Ulcer; Sulfasalazine; Tumor Necrosis Factor-alpha | 2002 |
[Combination therapy in rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine | 2003 |
Rheumatoid arthritis: more aggressive approach improves outlook.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Complementary Therapies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Time Factors | 2004 |
Rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Minocycline; Penicillamine; Receptors, Tumor Necrosis Factor; Sulfasalazine | 2003 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Factors; Isoxazoles; Leflunomide; Methotrexate; Sulfasalazine | 2004 |
[Armentarium and strategies for the treatment of rheumatoid arthritis].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Family Practice; Humans; Hydroxychloroquine; Meta-Analysis as Topic; Methotrexate; Rheumatology; Risk Assessment; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2005 |
Medical therapy: where are we now?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Methotrexate; Sulfasalazine; Treatment Outcome | 2006 |
Rheumatoid arthritis and reproduction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lactation; Methotrexate; Parity; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy, High-Risk; Sulfasalazine; Tumor Necrosis Factor-alpha | 2007 |
[Effective combination therapy of TNF antagonists with DMARDs].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cysteine; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Tumor Necrosis Factor-alpha | 2007 |
Treatment, management, and monitoring of established rheumatoid arthritis.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Drug Therapy, Combination; Etanercept; Humans; Hydrotherapy; Hydroxychloroquine; Immunoconjugates; Immunoglobulin G; Infliximab; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Methotrexate; Physical Therapy Modalities; Primary Health Care; Prognosis; Quality of Life; Receptors, Tumor Necrosis Factor; Rituximab; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2007 |
The BeSt story: on strategy trials in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Humans; Hydroxychloroquine; Infliximab; Methotrexate; Prednisolone; Sulfasalazine | 2009 |
[The goal for the treatment of rheumatoid arthritis should be remission].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Finland; Glucocorticoids; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine | 2010 |
The treatment of rheumatoid arthritis during pregnancy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Methotrexate; Pregnancy; Pregnancy Complications; Sulfasalazine; Tumor Necrosis Factor-alpha | 2011 |
Immunotherapies in rheumatologic disorders.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Azathioprine; Certolizumab Pegol; Colchicine; Cyclophosphamide; Cyclosporine; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoconjugates; Immunoglobulin Fab Fragments; Immunoglobulin G; Infliximab; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Methotrexate; Minocycline; Mycophenolic Acid; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rheumatic Diseases; Rituximab; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2012 |
[Update on Current Care Guidelines. Rheumatoid Arthritis (RA)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Decision Making; Exercise Therapy; Glucocorticoids; Humans; Hydroxychloroquine; Methotrexate; Practice Guidelines as Topic; Referral and Consultation; Sulfasalazine | 2015 |
The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Drug Therapy, Combination; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Methotrexate; Quality of Life; Sulfasalazine | 2016 |
Challenges and treatment options for rheumatoid arthritis during pregnancy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Methotrexate; Pregnancy; Pregnancy Complications; Sulfasalazine; Treatment Outcome | 2016 |
Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Methotrexate; Pain Measurement; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome | 2017 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azathioprine; Biological Products; Cyclophosphamide; Cyclosporine; Female; Fetal Growth Retardation; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Pregnancy; Pregnancy Complications; Premature Birth; Rituximab; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2020 |
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Etanercept; Heart Failure; Humans; Hydroxychloroquine; Inflammation; Methotrexate; Myocardial Infarction; Myocardial Ischemia; Risk Factors; Stroke Volume; Sulfasalazine | 2021 |
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, Type 2; Etanercept; Humans; Hydroxychloroquine; Immunomodulating Agents; Immunosuppression Therapy; Immunosuppressive Agents; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-1beta; Methotrexate; Sulfasalazine | 2022 |
What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Methotrexate; Practice Guidelines as Topic; Sulfasalazine | 2023 |
78 trial(s) available for hydroxychloroquine and sulfasalazine
| Article | Year |
|---|---|
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up.
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Evaluation; Follow-Up Studies; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; Sulfasalazine | 1990 |
Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Double-Blind Method; Female; Health Surveys; Humans; Hydroxychloroquine; Male; Middle Aged; Netherlands; Reproducibility of Results; Sensitivity and Specificity; Sulfasalazine; Surveys and Questionnaires | 1990 |
Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Arthrography; Clinical Trials as Topic; Double-Blind Method; Female; Foot; Hand; Humans; Hydroxychloroquine; Male; Middle Aged; Prospective Studies; Random Allocation; Severity of Illness Index; Sulfasalazine; Time Factors; Wrist Joint | 1989 |
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Sulfasalazine; Time Factors | 1989 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical Trials as Topic; Gastrointestinal Diseases; Glomerulonephritis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myasthenia Gravis; Myositis; Pemphigus; Penicillamine; Pyrithioxin; Sulfasalazine; Thrombocytopenia | 1986 |
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Receptors, Interleukin-2; Severity of Illness Index; Sulfasalazine | 1995 |
Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Sulfasalazine | 1993 |
Validity of single variables and indices to measure disease activity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Blood Sedimentation; C-Reactive Protein; Disabled Persons; Hemoglobins; Humans; Hydroxychloroquine; Joints; Methotrexate; Pain; Reproducibility of Results; Severity of Illness Index; Sulfasalazine | 1993 |
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Cri
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Discriminant Analysis; Europe; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Radiography; Reproducibility of Results; Severity of Illness Index; Societies, Medical; Sulfasalazine; Treatment Outcome; United States; World Health Organization | 1996 |
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Remission Induction; Sulfasalazine; Treatment Outcome | 1996 |
Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers.
Topics: Arthritis, Rheumatoid; Biomarkers; Double-Blind Method; Evaluation Studies as Topic; Humans; Hydroxychloroquine; International Cooperation; Outcome Assessment, Health Care; Prognosis; Sulfasalazine | 1996 |
Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Middle Aged; Sulfasalazine; Treatment Outcome | 1996 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisolone; Remission Induction; Sulfasalazine | 1999 |
Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Hydroxychloroquine; Radiography; Randomized Controlled Trials as Topic; Sulfasalazine | 2000 |
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Penicillamine; Prospective Studies; Sulfasalazine | 2000 |
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prednisolone; Remission Induction; Sulfasalazine; Treatment Outcome | 2002 |
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Sulfasalazine; Treatment Outcome | 2002 |
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Drug Therapy, Combination; Early Diagnosis; Employment; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Insurance Benefits; Male; Methotrexate; Middle Aged; Pensions; Prednisolone; Sulfasalazine | 2004 |
Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Therapy, Combination; E-Selectin; Female; Health Status; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prospective Studies; Severity of Illness Index; Sulfasalazine; Thrombomodulin; Treatment Outcome | 2004 |
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisolone; Remission Induction; Sick Leave; Sulfasalazine; Time Factors; Work Capacity Evaluation | 2005 |
Combination therapies in spondyloarthropathies.
Topics: Adult; Arthritis; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Radiography; Spondylarthropathies; Sulfasalazine; Treatment Outcome | 2004 |
Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Female; Gold; Health Status; Humans; Hydroxychloroquine; Immunoglobulin G; Injections, Intramuscular; Injections, Subcutaneous; Male; Middle Aged; Prospective Studies; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2006 |
Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arachidonic Acid; Arthritis, Rheumatoid; Cardiovascular Diseases; Dietary Supplements; Dinoprostone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosanoids; Female; Fish Oils; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Risk Factors; Sulfasalazine; Thromboxane A2 | 2006 |
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Isoxazoles; Kaplan-Meier Estimate; Leflunomide; Male; Methotrexate; Middle Aged; Prednisone; Sulfasalazine; Treatment Failure; Treatment Outcome | 2007 |
Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fish Oils; Glucocorticoids; Humans; Hydroxychloroquine; Longitudinal Studies; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2007 |
Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Single-Blind Method; Sulfasalazine | 2008 |
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Topics: Adult; Aged; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Pain Measurement; Remission Induction; Sulfasalazine; Treatment Outcome | 2008 |
Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen Type II; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisolone; Remission Induction; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2008 |
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisolone; Sulfasalazine; Treatment Outcome | 2009 |
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Finland; Follow-Up Studies; Foot Joints; Hand Joints; Humans; Hydroxychloroquine; Longitudinal Studies; Methotrexate; Prednisolone; Radiography; Sulfasalazine; Treatment Outcome | 2010 |
Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.
Topics: Absorptiometry, Photon; Adiponectin; Adipose Tissue; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Apolipoproteins; Arthritis, Rheumatoid; Body Composition; Bone Density; Bone Remodeling; Female; Humans; Hydroxychloroquine; Infliximab; Insulin-Like Growth Factor I; Leptin; Male; Methotrexate; Middle Aged; Radioimmunoassay; Sulfasalazine | 2010 |
Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
Topics: Adolescent; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Drug Combinations; Epidemiologic Methods; Female; Glucocorticoids; Humans; Hydroxychloroquine; Infliximab; Injections, Intra-Articular; Male; Methotrexate; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Drug Resistance; Drug Therapy, Combination; Female; Foot Bones; Hand Bones; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Radiography; Sulfasalazine; Tumor Necrosis Factor-alpha | 2012 |
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Radiography; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2012 |
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Induction Chemotherapy; Injections, Intramuscular; Male; Methotrexate; Middle Aged; Recovery of Function; Sulfasalazine | 2013 |
Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cotinine; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Longitudinal Studies; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Smoking; Sulfasalazine; Treatment Outcome | 2012 |
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Hydroxychloroquine; Induction Chemotherapy; Infliximab; Longitudinal Studies; Male; Methotrexate; Middle Aged; Prednisolone; Sulfasalazine; Treatment Outcome | 2013 |
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Infliximab; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine; Treatment Outcome | 2013 |
Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Sulfasalazine; Treatment Outcome | 2013 |
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Absorptiometry, Photon; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Female; Hand Bones; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Sulfasalazine; Sweden; Time Factors; Treatment Outcome | 2013 |
Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Health Status; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Prognosis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Symptom Assessment; Time Factors; Treatment Outcome | 2013 |
Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Health Status; Humans; Hydroxychloroquine; Immunoglobulin G; Joints; Male; Methotrexate; Middle Aged; Prognosis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome | 2013 |
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisone; Radiography; Remission Induction; Single-Blind Method; Sulfasalazine; Treatment Outcome | 2014 |
Therapies for active rheumatoid arthritis after methotrexate failure.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Treatment Failure | 2013 |
Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Infliximab; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Pensions; Sick Leave; Sulfasalazine; Sweden; Treatment Outcome; Young Adult | 2013 |
Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Docosahexaenoic Acids; Double-Blind Method; Drug Therapy, Combination; Early Medical Intervention; Eicosapentaenoic Acid; Female; Fish Oils; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Remission Induction; Sulfasalazine; Treatment Outcome | 2015 |
Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progression; Female; Humans; Hydroxychloroquine; Male; Metacarpal Bones; Methotrexate; Middle Aged; Prednisone; Sulfasalazine | 2015 |
Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Diagnosis; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Pain Measurement; Patient Satisfaction; Prednisone; Quality of Life; Range of Motion, Articular; Recovery of Function; Remission Induction; Severity of Illness Index; Single-Blind Method; Sulfasalazine; Time Factors; Treatment Outcome | 2013 |
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Radiography; Smoking; Sulfasalazine; Treatment Outcome | 2015 |
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Health Services; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Quality-Adjusted Life Years; Sick Leave; Sulfasalazine; Treatment Failure; Treatment Outcome | 2015 |
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Injections, Intramuscular; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Single-Blind Method; Sulfasalazine; Treatment Outcome | 2014 |
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Topics: Adipokines; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Chitinase-3-Like Protein 1; Disease Progression; Drug Therapy, Combination; Epidermal Growth Factor; Female; Foot Joints; Hand Joints; Humans; Hydroxychloroquine; Infliximab; Interleukin-6; Lectins; Leptin; Logistic Models; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Multivariate Analysis; Prognosis; Radiography; Receptors, Tumor Necrosis Factor, Type I; Resistin; Serum Amyloid A Protein; Severity of Illness Index; Sulfasalazine; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2015 |
Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Certolizumab Pegol; Cholesterol; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin Fab Fragments; Immunoglobulin G; Infliximab; Lipid Metabolism; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2014 |
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antibody Specificity; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Disease Progression; Drug Therapy, Combination; Female; Fibrinogen; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Phosphopyruvate Hydratase; Radiography; Sulfasalazine; Sweden; Vimentin | 2016 |
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Infliximab; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Sulfasalazine; Sweden; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Finland; Follow-Up Studies; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Multivariate Analysis; Practice Patterns, Physicians'; Prednisolone; Remission Induction; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Single-Blind Method; Sulfasalazine; Time Factors; Treatment Outcome | 2016 |
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Sick Leave; Sulfasalazine; Sweden; Time Factors; Treatment Outcome | 2016 |
Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Etanercept; Female; Health Care Costs; Humans; Hydroxychloroquine; Male; Markov Chains; Methotrexate; Middle Aged; Quality-Adjusted Life Years; Sulfasalazine; Time Factors | 2016 |
Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Lipoproteins, HDL; Male; Methotrexate; Middle Aged; Sulfasalazine | 2017 |
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Female; Gastritis; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Ileus; Incidence; Infections; Intestinal Obstruction; Linear Models; Male; Methotrexate; Middle Aged; Pancreatitis; Pneumonia; Respiratory Tract Infections; Sulfasalazine; Urinary Tract Infections | 2017 |
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Topics: Adamantane; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Janus Kinase 3; Male; Middle Aged; Niacinamide; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2017 |
Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Canada; Disability Evaluation; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Remission Induction; Sulfasalazine; Time Factors; Treatment Outcome; United States; Young Adult | 2017 |
Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Joints; Male; Methotrexate; Middle Aged; Prednisone; Radiography; Remission Induction; Severity of Illness Index; Single-Blind Method; Sulfasalazine; Time Factors; Treatment Outcome | 2018 |
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Injections, Subcutaneous; Leflunomide; Male; Methotrexate; Middle Aged; Sulfasalazine; Treatment Outcome | 2019 |
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Deprescriptions; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Leflunomide; Male; Methotrexate; Middle Aged; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2020 |
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Topics: Adult; Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Leflunomide; Male; Methotrexate; Middle Aged; Prognosis; Rheumatoid Factor; Sulfasalazine; Surveys and Questionnaires; Treatment Outcome | 2019 |
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Topics: Adult; Antirheumatic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Janus Kinase Inhibitors; Magnetic Resonance Imaging; Male; Mesalamine; Methotrexate; Middle Aged; Sacroiliac Joint; Spondylitis, Ankylosing; Sulfasalazine; Treatment Outcome | 2019 |
Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Quality of Life; Sulfasalazine; Surveys and Questionnaires; Treatment Outcome | 2019 |
Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Male; Middle Aged; Pain Management; Pain Measurement; Sulfasalazine; Sweden; Time Factors; Treatment Outcome | 2021 |
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Topics: Abatacept; Adult; Aged; Anti-Citrullinated Protein Antibodies; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; C-Reactive Protein; Certolizumab Pegol; Denmark; Drug Therapy, Combination; Early Medical Intervention; Female; Finland; Glucocorticoids; Humans; Hydroxychloroquine; Injections, Intra-Articular; Male; Methotrexate; Middle Aged; Netherlands; Norway; Prednisolone; Rheumatoid Factor; Severity of Illness Index; Single-Blind Method; Sulfasalazine; Sweden; Treatment Outcome | 2020 |
The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Neoplasm Recurrence, Local; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2021 |
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Leflunomide; Male; Methotrexate; Middle Aged; Radiography; Sulfasalazine; Symptom Flare Up; Ultrasonography | 2021 |
Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine; Treatment Outcome | 2022 |
Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Infliximab; Methotrexate; Sulfasalazine; Treatment Outcome | 2022 |
Hydroxychloroquine Effects on THP-1 Macrophage Cholesterol Handling: Cell Culture Studies Corresponding to the TARGET Cardiovascular Trial.
Topics: Arthritis, Rheumatoid; Atherosclerosis; Cell Culture Techniques; Cholesterol; Humans; Hydroxychloroquine; Interferon-gamma; Macrophages; Mixed Function Oxygenases; RNA, Messenger; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2022 |
95 other study(ies) available for hydroxychloroquine and sulfasalazine
| Article | Year |
|---|---|
Long-term second-line treatment: a prospective drug survival study.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Humans; Hydroxychloroquine; Penicillamine; Prospective Studies; Sulfasalazine; Survival Analysis | 1992 |
Drugs for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Azathioprine; Costs and Cost Analysis; Drugs, Investigational; Humans; Hydroxychloroquine; Methotrexate; Monitoring, Physiologic; Organogold Compounds; Penicillamine; Sulfasalazine | 1991 |
Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Male; Middle Aged; Penicillamine; Peptic Ulcer; Sulfasalazine | 1991 |
Long-term radiographic progression in treated rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Penicillamine; Radiography; Sulfasalazine; Time Factors | 1990 |
Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Female; HLA-B8 Antigen; HLA-DR3 Antigen; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglobulin M; Middle Aged; Sulfasalazine; Thrombocytopenia | 1990 |
Drugs for rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Gold; Humans; Hydroxychloroquine; Methotrexate; Penicillamine; Salicylates; Sulfasalazine | 1989 |
"Disease-modifying" drugs in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Immunosuppressive Agents; Penicillamine; Sulfasalazine | 1985 |
Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Gold; Humans; Hydroxychloroquine; Methotrexate; Penicillamine; Sulfasalazine | 1987 |
Rheumatoid arthritis: a pharmacologic overview.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Humans; Hydroxychloroquine; Immunosuppressive Agents; Penicillamine; Sulfasalazine | 1988 |
How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine?
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Blood Viscosity; Chloroquine; Drug Administration Schedule; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Male; Penicillamine; Sulfasalazine | 1988 |
[Chronic regional enterocolitis (Crohn's disease) in juveniles].
Topics: Adolescent; Blood Transfusion; Child; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Male; Prednisolone; Sulfasalazine | 1967 |
A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxychloroquine; Organogold Compounds; Penicillamine; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 1993 |
Optimizing the assessment of disease activity during treatment with anti-rheumatoid drugs.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cytidine Deaminase; Female; Gold; Humans; Hydroxychloroquine; Male; Middle Aged; Orosomucoid; Penicillamine; Prospective Studies; Severity of Illness Index; Sulfasalazine | 1993 |
Treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Remission Induction; Sulfasalazine | 1996 |
Treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Placebos; Sulfasalazine | 1996 |
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Gold; Humans; Hydroxychloroquine; Male; Middle Aged; Minocycline; Retrospective Studies; Sulfasalazine; Treatment Outcome | 1997 |
A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a county hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Child; Drug Therapy, Combination; Gold; Hospitals, County; Humans; Hydroxychloroquine; Methotrexate; Middle Aged; Retrospective Studies; Sulfasalazine | 1997 |
HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments.
Topics: Adult; Aged; Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Epitopes; Female; Histocompatibility Testing; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Patient Selection; Sulfasalazine; Treatment Outcome | 1998 |
Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Dihydropteridine Reductase; Female; Gold Compounds; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Neopterin; Rheumatoid Factor; Sulfasalazine | 1998 |
Combination therapy in rheumatoid arthritis: a comment.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine; Treatment Outcome | 1999 |
Treatment considerations in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Patient Selection; Risk; Sulfasalazine; Time Factors; Treatment Outcome | 1997 |
The changing face of rheumatoid arthritis therapy: results of serial surveys.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Data Collection; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine | 2000 |
Drugs for rheumatoid arthritis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Central Nervous System Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Methotrexate; Nausea; Osteoporosis; Plasmapheresis; Prednisone; Sulfasalazine; Tumor Necrosis Factor-alpha | 2000 |
Conventional DMARD options for patients with a suboptimal response to methotrexate.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Sulfasalazine | 2001 |
Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Drug Combinations; Female; Glucosamine; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Organogold Compounds; Retrospective Studies; Sulfasalazine; Treatment Outcome | 2002 |
[Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Topics: Adult; Anorexia; Antirheumatic Agents; Arthritis, Rheumatoid; Exanthema; Female; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Nausea; Penicillamine; Phytotherapy; Plant Preparations; Retrospective Studies; Sinomenium; Sulfasalazine | 2002 |
[Diagnosis and treatment of rheumatoid arthritis].
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclosporins; Diagnosis, Differential; Exercise Therapy; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Rheumatoid Factor; Sulfasalazine | 2002 |
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Isoxazoles; Leflunomide; Methotrexate; Placebos; Prednisolone; Randomized Controlled Trials as Topic; Sulfasalazine; Time Factors | 2003 |
Methotrexate is the leading DMARD in Finland.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Finland; Humans; Hydroxychloroquine; Insurance, Health; Methotrexate; Rheumatic Diseases; Sulfasalazine | 2003 |
[Classification of dermatologic manifestations in lupus erythematosus].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Antimalarials; Clinical Trials as Topic; Dapsone; Dermatologic Agents; Diagnosis, Differential; Drug Combinations; Female; Glucosamine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Infant, Newborn; Isotretinoin; Keratolytic Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Male; Middle Aged; Skin; Sulfasalazine; Thalidomide; Thrombosis; Ultraviolet Therapy; Vasculitis | 2003 |
Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Clinical Protocols; Cohort Studies; Female; Hand; Health Status; Humans; Hydroxychloroquine; Injections, Intra-Articular; Injections, Intramuscular; Male; Methotrexate; Methylprednisolone; Middle Aged; Rheumatoid Factor; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2003 |
Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Health Services Research; Humans; Hydroxychloroquine; Male; Managed Care Programs; Methotrexate; Middle Aged; Midwestern United States; New England; Sulfasalazine; Time Factors; Treatment Outcome | 2000 |
[When to begin rheumatism treatment? Initial combination therapy helps fastest].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Humans; Hydroxychloroquine; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Prednisolone; Randomized Controlled Trials as Topic; Sulfasalazine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
[Symmetric polyarthritis in a patient with Churg-Strauss syndrome].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Azathioprine; Churg-Strauss Syndrome; Cyclophosphamide; Drug Therapy, Combination; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Recurrence; Sulfasalazine | 2005 |
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Case-Control Studies; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Odds Ratio; Regression Analysis; Risk Factors; Sulfasalazine | 2006 |
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Folic Acid; Gene Frequency; Genotype; Haplotypes; Health Status; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Severity of Illness Index; Sulfasalazine; Tetrahydrofolate Dehydrogenase | 2008 |
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisolone; Retrospective Studies; Sulfasalazine | 2008 |
Chikungunya virus aches and pains: an emerging challenge.
Topics: Alphavirus Infections; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Chikungunya virus; Chronic Disease; Humans; Hydroxychloroquine; Methotrexate; Musculoskeletal Diseases; Sulfasalazine | 2008 |
Disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Methotrexate; Sulfasalazine | 2009 |
[Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Protocols; Colombia; Diagnostic Services; Direct Service Costs; Disease Management; Drug Costs; Drug Therapy, Combination; Etanercept; Health Care Costs; Hospital Costs; Hospitals, University; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Meloxicam; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Thiazines; Thiazoles | 2009 |
Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection.
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Carriers; Hepatitis C, Chronic; Humans; Hydroxychloroquine; Interferon alpha-2; Interferon-alpha; Joints; Male; Middle Aged; Peptides, Cyclic; Polyethylene Glycols; Recombinant Proteins; Sulfasalazine; Treatment Outcome | 2010 |
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; India; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retrospective Studies; Sulfasalazine; Time Factors | 2012 |
Post-chikungunya chronic arthritis--our experience with DMARDs over two year follow up.
Topics: Adult; Aged; Alphavirus Infections; Antirheumatic Agents; Arthritis, Rheumatoid; Chikungunya Fever; Chikungunya virus; Chronic Disease; Drug Therapy, Combination; Epidemics; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Severity of Illness Index; Sulfasalazine; Treatment Outcome; Young Adult | 2011 |
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Narcotics; Retrospective Studies; Sulfasalazine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disability Evaluation; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Health Status; Humans; Hydroxychloroquine; Logistic Models; Male; Methotrexate; Middle Aged; Sulfasalazine; Treatment Failure; Treatment Outcome | 2013 |
Making rational treatment decisions in rheumatoid arthritis when methotrexate fails.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine | 2013 |
Conventional triple therapy as good as etanercept for uncontrolled rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Treatment Failure | 2013 |
Not better but quite good: effects on work loss of combination treatment for rheumatoid arthritis with and without biological agents.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Pensions; Sick Leave; Sulfasalazine | 2013 |
Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement; Female; Finland; Humans; Hydroxychloroquine; Male; Methotrexate; Registries; Sulfasalazine | 2013 |
[Rheumatoid arthritis: lower work loss during treatment with biologicals?--Modern treatment principles reduce work loss in rheumatoid arthritis].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Pensions; Sick Leave; Sulfasalazine | 2013 |
Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: a nationwide population-based cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Periodontitis; Receptors, Tumor Necrosis Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sulfasalazine; Tumor Necrosis Factor-alpha | 2013 |
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cholesterol; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Male; Methotrexate; Methylprednisolone; Middle Aged; Severity of Illness Index; Sulfasalazine; Triglycerides; Young Adult | 2013 |
Psoriatic arthritis treatment and the risk of herpes zoster.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Azathioprine; Cyclosporine; Drug Combinations; Drug Therapy, Combination; Etanercept; Female; Glucosamine; Herpes Zoster; Humans; Hydroxychloroquine; Incidence; Infliximab; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retrospective Studies; Sulfasalazine; Tumor Necrosis Factor-alpha | 2016 |
Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes.
Topics: Antirheumatic Agents; Chondrocytes; Dexamethasone; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Enzymologic; Glucocorticoids; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Intramolecular Oxidoreductases; Methotrexate; Osteoarthritis, Knee; Primary Cell Culture; Prostaglandin-E Synthases; Real-Time Polymerase Chain Reaction; Sulfasalazine | 2015 |
A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Data Interpretation, Statistical; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Joints; Male; Methotrexate; Middle Aged; Models, Biological; Predictive Value of Tests; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome; Young Adult | 2015 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Employment; Female; Finland; Health Status; Humans; Hydroxychloroquine; Hyperlipidemias; Hypertension; Male; Methotrexate; Middle Aged; Neoplasms; Patient Outcome Assessment; Respiratory Tract Diseases; Sulfasalazine; Tumor Necrosis Factor-alpha | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort Studies; Disease Progression; Female; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Proportional Hazards Models; Remission Induction; Sulfasalazine; Time-to-Treatment; Treatment Outcome | 2015 |
Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Topics: Adalimumab; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Hepatitis C, Chronic; Humans; Hydroxychloroquine; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retrospective Studies; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Logistic Models; Male; Medicare Part B; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Sulfasalazine; Time Factors; Treatment Outcome; United States; Young Adult | 2015 |
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antibodies; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Receptors, Tumor Necrosis Factor; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Sulfasalazine; Treatment Outcome; United States | 2015 |
Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Inhibitor of Apoptosis Proteins; Male; Methotrexate; Middle Aged; Proto-Oncogene Mas; Randomized Controlled Trials as Topic; Sulfasalazine; Survivin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Certolizumab Pegol; Cohort Studies; Cyclophosphamide; Etanercept; Female; Humans; Hydroxychloroquine; Hypertension; Incidence; Infliximab; Male; Methotrexate; Middle Aged; Minocycline; Penicillamine; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sulfasalazine; Tumor Necrosis Factor-alpha | 2016 |
Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Sulfasalazine; Time Factors; United States | 2016 |
Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed Diagnosis; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; India; Male; Methotrexate; Middle Aged; Sulfasalazine; Treatment Outcome | 2016 |
Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Databases, Factual; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Methotrexate; Middle Aged; Propensity Score; Retrospective Studies; Risk Factors; Sulfasalazine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; United States; Veterans Health | 2017 |
Improving patient-centred care for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Decision Making; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Methotrexate; Patient Participation; Patient-Centered Care; Quality Improvement; Sulfasalazine | 2016 |
Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Medication Adherence; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2016 |
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Chitinase-3-Like Protein 1; Decision Support Techniques; Drug Therapy, Combination; Epidermal Growth Factor; Female; Humans; Hydroxychloroquine; Infliximab; Interleukin-6; Leptin; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor, Type I; Resistin; Serum Amyloid A Protein; Severity of Illness Index; Sulfasalazine; Treatment Failure; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2017 |
Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Case-Control Studies; Etanercept; Female; Herpes Zoster; Herpes Zoster Ophthalmicus; Humans; Hydroxychloroquine; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Odds Ratio; Risk Factors; Rituximab; Severity of Illness Index; Sulfasalazine; Taiwan; Time Factors; Tumor Necrosis Factor-alpha; Young Adult | 2017 |
Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cohort Studies; Drug Therapy, Combination; Female; Finland; Glucocorticoids; Humans; Hydroxychloroquine; Logistic Models; Male; Methotrexate; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Remission Induction; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2017 |
Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response.
Topics: ADAMTS Proteins; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Butyrophilins; CpG Islands; DNA Methylation; Epigenesis, Genetic; Fibroblasts; Humans; Hydroxychloroquine; Joint Capsule; Methotrexate; Sulfasalazine; T-Lymphocytes | 2017 |
Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana.
Topics: Adult; Arthritis, Rheumatoid; Body Mass Index; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prevalence; Sulfasalazine; Tertiary Care Centers | 2017 |
Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroscopy; Biopsy; Case-Control Studies; Cell Differentiation; Down-Regulation; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lymphocyte Activation; Male; Methotrexate; Middle Aged; Plasma Cells; Principal Component Analysis; Remission Induction; Sequence Analysis, RNA; Sulfasalazine; Synovial Membrane; T-Lymphocytes; Transcriptome | 2017 |
Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Kaplan-Meier Estimate; Linear Models; Longitudinal Studies; Male; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Remission Induction; Risk Factors; Sulfasalazine; Time Factors; Treatment Outcome | 2017 |
A Bayesian model that jointly considers comparative effectiveness research and patients' preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Comparative Effectiveness Research; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Network Meta-Analysis; Patient Preference; Practice Guidelines as Topic; Sulfasalazine; Treatment Outcome | 2018 |
Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Humans; Hydroxychloroquine; Incidence; Male; Methotrexate; Middle Aged; Protective Factors; Retrospective Studies; Risk Factors; Stroke; Sulfasalazine; Taiwan; Treatment Outcome | 2018 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; Humans; Hydroxychloroquine; Hypertension; Incidence; Leflunomide; Linear Models; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2018 |
Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydroxychloroquine; Linear Models; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Sex Factors; Sulfasalazine; Treatment Outcome | 2018 |
Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Male; Medication Adherence; Methotrexate; Middle Aged; Retrospective Studies; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2019 |
Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Therapy, Combination; Etanercept; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prognosis; Protein-Arginine Deiminase Type 4; Sulfasalazine; Treatment Outcome | 2019 |
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Societies, Medical; Sulfasalazine | 2018 |
Genetic and epigenetic alteration of the programmed cell death 1 in rheumatoid arthritis.
Topics: Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Humans; Hydroxychloroquine; Leflunomide; Male; Methotrexate; Odds Ratio; Polymorphism, Single Nucleotide; Programmed Cell Death 1 Receptor; Reverse Transcriptase Polymerase Chain Reaction; Rheumatoid Factor; RNA, Messenger; Sulfasalazine; Transcriptome; Treatment Failure; Treatment Outcome | 2019 |
Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromatography, Thin Layer; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Sulfasalazine | 2019 |
The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lymphocytes; Male; Methotrexate; Middle Aged; Neutrophils; Prognosis; Sulfasalazine; Treatment Failure | 2019 |
Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Topics: Abatacept; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Biological Products; British Columbia; Chloroquine; Cohort Studies; Cyclophosphamide; Cyclosporine; Deprescriptions; Female; Glucocorticoids; Gold Compounds; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Leflunomide; Logistic Models; Maternal Age; Methotrexate; Mycophenolic Acid; Odds Ratio; Preconception Care; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, First; Rheumatology; Rituximab; Sulfasalazine; Tumor Necrosis Factor Inhibitors | 2020 |
The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009-2018).
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; China; Cohort Studies; Female; Glucocorticoids; Humans; Hydroxychloroquine; Leflunomide; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Patient Reported Outcome Measures; Remission Induction; Retrospective Studies; Sex Factors; Sulfasalazine | 2020 |
Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chi-Square Distribution; Female; Humans; Hydroxychloroquine; Leflunomide; Male; Methotrexate; Middle Aged; Rheumatoid Factor; Statistics, Nonparametric; Sulfasalazine | 2020 |
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Registries; Sulfasalazine; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors; United States | 2021 |
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Heart Disease Risk Factors; Humans; Hydroxychloroquine; Safety; SARS-CoV-2; Sulfasalazine; Time Factors | 2020 |
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Sulfasalazine; Survival Rate; Treatment Outcome | 2021 |
Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Odds Ratio; Registries; Sulfasalazine; Sweden; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2021 |
Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset.
Topics: Azathioprine; Communicable Disease Control; COVID-19; Drug Prescriptions; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Pandemics; Sulfasalazine; Time Factors | 2022 |